Home » Topics » BioWorld Science

BioWorld Science
RSS

BioCryst doses first patient in phase I trial of intravenous galidesivir

Jan. 2, 2019

ALCAM-EGFR axis discovered as therapeutic target in multiple myeloma

Jan. 2, 2019

New PDE9 inhibitors presented by Merck & Co.

Jan. 2, 2019

Dosing begins in phase III study of Tyvyt for first-line esophageal squamous cell carcinoma

Jan. 2, 2019

Hanmi Science describes KDM1A inhibitors

Jan. 2, 2019

Cadila Healthcare synthesizes NLRP3 inhibitors

Jan. 2, 2019

Chiesi Farmaceutici patents new MAPK 14 inhibitors

Jan. 2, 2019

NicOx presents new compounds for eye disorders

Jan. 2, 2019

Patient enrollment ongoing in phase I study of BOS-172738

Jan. 2, 2019

Epigenetic analysis boosts malaria pathogenesis understanding

Jan. 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...